Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:42:26 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:CTMX - CYTOMX THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CTMX - Q1.91.67·3.291.01.67-0.06-3.5505.67411,3631.72  1.75  1.6352.855  1.0416:17:45Apr 0815 min RT 2¢

Recent Trades - Last 10 of 1363
Time ETExPriceChangeVolume
16:17:45Q1.67-0.0611,629
16:15:54Q1.6712-0.058831
16:00:02Q1.67-0.0638
16:00:02Q1.67-0.06216
16:00:02Q1.67-0.06184
16:00:02Q1.67-0.064,000
16:00:02Q1.67-0.06300
16:00:02Q1.67-0.065
16:00:02Q1.67-0.0616,345
16:00:02Q1.67-0.06100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-08 08:00U:CTMXNews ReleaseCytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
2024-04-03 08:00U:CTMXNews ReleaseCytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY(TM) T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
2024-03-21 08:00U:CTMXNews ReleaseCytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
2024-03-18 08:00U:CTMXNews ReleaseCytomX Therapeutics Announces Milestone Achievement in PROBODY(TM) T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
2024-03-11 16:10U:CTMXNews ReleaseCytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
2024-03-04 08:00U:CTMXNews ReleaseCytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
2024-02-27 08:00U:CTMXNews ReleaseCytomX Therapeutics to Present at Upcoming March Investor Conferences
2024-01-24 08:00U:CTMXNews ReleaseCytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody ‚ ® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b
2024-01-12 08:00U:CTMXNews ReleaseCytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference
2024-01-04 08:00U:CTMXNews ReleaseCytomX Therapeutics Outlines 2024 Company Priorities and Milestones
2023-12-21 08:00U:CTMXNews ReleaseCytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-07 16:15U:CTMXNews ReleaseCytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-11-01 08:00U:CTMXNews ReleaseCytomX Therapeutics to Present at Upcoming November Investor Conferences
2023-10-31 08:00U:CTMXNews ReleaseCytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023
2023-10-30 08:00U:CTMXNews ReleaseCytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting
2023-10-18 16:30U:CTMXNews ReleaseCytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference
2023-09-05 16:05U:CTMXNews ReleaseCytomX Therapeutics to Present at Upcoming September Investor Conferences
2023-08-10 16:05U:CTMXNews ReleaseCytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference
2023-08-08 16:15U:CTMXNews ReleaseCytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
2023-08-01 08:00U:CTMXNews ReleaseCytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023